SecBot SecBot
SECBOTREPLAY Home › Report › DNLI

DNLI · Denali Therapeutics announced the sale of its Rare Pediatric Disease…

Denali Therapeutics Inc. · PRESS-RELEASE filed Jun 18, 2026 at 08:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 18, 2026 at 08:00 ET

Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in gross proceeds. The PRV was awarded following FDA approval of AVLAYAH for Hunter syndrome in March 2026. The non-dilutive cash infusion strengthens Denali's financial flexibility and will fund its clinical pipeline, including programs for lysosomal storage disorders and neurodegenerative diseases.

  • Denali entered a definitive agreement to sell its Rare Pediatric Disease PRV for $195 million gross proceeds.
  • The PRV was awarded after FDA accelerated approval of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome in March 2026.
  • Proceeds will support Denali's TransportVehicle-enabled clinical pipeline, including DNL126, DNL593, DNL952, and DNL628.
  • The transaction is subject to customary closing conditions, including HSR Act waiting period expiration.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access